Altimmune, Inc. (NASDAQ:ALT) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET

Company Participants

Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune
Vipin Garg - Chief Executive Officer
Scott Harris - Chief Medical Officer
Andrew Shutterly - Acting Chief Financial Officer
Scot Roberts - Chief Scientific Officer

Conference Call Participants

Liam Hiester - Piper Sandler
Seema Sheoran - Evercore
Omari Baruti - Goldman Sachs
William Wood - B. Riley Securities
Jon Wolleben - Citizens JMP

Operator

Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, Lee Roth of Burns McClellan, Investor Relations Advisors to Altimmune.

Lee Roth

Thanks, Gigi. Good morning, everyone. Thank you for participating on the Altimmune second quarter 2024 financial results and business update conference call.

Members of the Altimmune team joining me today are Vipin Garg, our Chief Executive Officer; Scott Harris, our Chief Medical Officer; Ray Jordt, our Chief Business Officer; Andrew Shutterly, our acting Chief Financial Officer; and Scot Roberts, our Chief Scientific Officer.

Following prepared remarks from Vipin, Scott Harris and Andrew, we'll hold a Q&A session. As a reminder, our press release with our Q2 2024 financial results was issued this morning and can be found on the IR section of the company's website.

Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those indicated.

For a discussion of some of the risks and the factors that could impact the company's future results and operations, please refer to the risk factors and other cautionary statements contained in our filings with the SEC. I'll also direct you to read the forward-looking statement disclaimer in our press release issued earlier today and now available on our website.

Any statements made during this call speak only as of today's date, Thursday, August 8, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today. As a reminder, this call is being recorded and will be available for audio replay on the Altimmune website.